GlassScriptPhysician profile
Christine Peebles
NPI 1790968758
$582.94
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $544 · 2022: $39.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $173.43 | 2021 | |
| Abbvie INC. | $122.69 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $76.26 | 2021 | |
| Novo Nordisk INC | $45.13 | 2021 | |
| Amgen INC. | $43.12 | 2021 | |
| Abbott Laboratories | $33.68 | 2021 | |
| Genentech USA, INC. | $16.93 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.88 | 2021 | |
| Amarin Pharma, INC. | $16.37 | 2021 | |
| Astellas Pharma US INC | $14.69 | 2021 | |
| Esperion Therapeutics, INC. | $12.26 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.50 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Peebles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.